Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on February 4, 2021. The filing discloses material information regarding the company's investment in Surface Ophthalmics, Inc. ("Surface"), a portfolio company in which Harrow holds a significant equity stake.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for Harrow Health, Inc. for the reporting period. The document focuses exclusively on a corporate development event rather than periodic financial performance.
Material Changes and Events
- Surface Ophthalmics Trial Update: On February 4, 2021, Surface Ophthalmics announced the first patient dosing in a Phase II trial for its drug candidate SURF-200 (betamethasone in Klarity vehicle) for the treatment of acute dry eye.
- Trial Details: The dose-ranging study will enroll 120-140 patients. The primary endpoint is a Symptom Improvement of one unit based on the University of North Carolina Dry Eye Management Scale by the eighth day.
- Harrow's Stake: Harrow Health owns 3,500,000 shares of Surface common stock, representing approximately 30% of Surface's issued and outstanding voting interests.
- Additional Rights: Harrow holds a mid-single digit royalty right on net sales of SURF-200.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on Harrow's overall outlook, or specific risk factors beyond the standard disclaimer that the summary is qualified by reference to the full press release filed as Exhibit 99.1. The success of the SURF-200 trial is contingent on clinical outcomes not yet determined.
Key Facts for Investor Verification
- Verify the full text of the Surface Ophthalmics press release (Exhibit 99.1) for complete trial protocol details.
- Confirm the current valuation and liquidity status of Harrow's 30% equity stake in Surface Ophthalmics.
- Monitor future filings for updates on the Phase II trial enrollment progress and primary endpoint results.
- Review the specific terms of the "mid-single digit royalty right" to understand potential future revenue streams from SURF-200.